3SBio's Total Assets for the quarter that ended in Dec. 2025 was $5,147 Mil.
During the past 12 months, 3SBio's average Total Assets Growth Rate was -5.10% per year.
During the past 3 years, the average Total Assets Growth Rate was 3.70% per year.
During the past 5 years, the average Total Assets Growth Rate was 3.70% per year.
During the past 10 years, the average Total Assets Growth Rate was 9.70% per year.
During the past 12 years, 3SBio's highest 3-Year average Total Assets Growth Rate was 67.50%. The lowest was 3.40%. And the median was 7.10%.
Total Assets is connected with ROA %. 3SBio's annualizedROA % for the quarter that ended in Dec. 2025 was 47.79%. Total Assets is also linked to Revenue through Asset Turnover. 3SBio's Asset Turnover for the quarter that ended in Dec. 2025 was 0.45.
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
3SBio's Asset Turnover for the quarter that ended in Dec. 2025 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
3SBio Total Assets Related Terms
3SBio Total Assets Historical Data
* Premium members only.
The historical data trend for 3SBio's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
3SBio's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
3SBio (TRSBF) has a Total Assets of $5,147 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on 3SBio and its competitors.
Is 3SBio's Total Assets too high?
3SBio's current Total Assets is $5,147 Mil. Overall, 3SBio has a GF Score™ of 90/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 3SBio's Total Assets compare to VRTX and REGN?
3SBio's Total Assets of $5,147 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on 3SBio and its competitors. 3SBio's current Total Assets is $5,147 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 3SBio stock overvalued right now?
Based on GuruFocus' analysis, 3SBio (TRSBF) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.61, compared to a current price of $2.15 — trading 33.5% above its estimated fair value. The current Total Assets is $5,147 Mil. 3SBio's overall GF Score™ is 90/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For 3SBio (TRSBF), the current Total Assets is $5,147 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 3SBio (TRSBF) Overvalued in 2026?
Based on GuruFocus' analysis, 3SBio stock appears to be overvalued.
The current stock price of $2.15 is trading 33.5% above its estimated GF Value™ of $1.61.
GuruFocus considers 3SBio to be Significantly Overvalued.
Key valuation signals for TRSBF:
Total Assets: $5,147 Mil
GF Value™: $1.61 vs. price of $2.15 (33.5% above fair value)
No single metric tells the full story. See the TRSBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
3SBio Inc is an investment holding company. It is a primary biotechnology company. The company is principally engaged in the development, production, marketing and sale of biopharmaceutical products in the People's Republic of China. The group has only one operating segment. It has presence in Chinese mainland, USA, Other countries/regions. The majority of revenue comes from USA. The core commercialized products of the group include several bio-pharmaceutical drugs, namely, TPIAO, recombinant human erythropoietin (rhEPO) products EPIAO and SEPO, Yisaipu and Cipterbin, and a small molecule drug, Mandi series of minoxidil drugs.
90GF Score
Get the complete analysis for TRSBF
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TRSBF has been successfully added to your 
